Polymorphism of the aldosterone synthase gene is not associated with progression of diabetic nephropathy, but associated with hypertension in type 2 diabetic patients

Nephrology

Volumn 13, Issue 6, 2008, Pages 492-499

  Ko, Gang Jee ^a   Kang, Young Sun ^a   Lee, Mi Hwa ^a   Song, Hye Kyoung ^a   Kim, Hyoung Kyu ^a   Cha, Dae Ryong ^a,b  

^a Korea University   (South Korea)

^b Korea University   (South Korea)

Author keywords

Aldosterone; Aldosterone synthase; Diabetic nephropathy; Polymorphism; Type 2 diabetes

Indexed keywords

ALDOSTERONE; ALDOSTERONE SYNTHASE; STEROIDOGENIC FACTOR 1;

ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ALDOSTERONE RELEASE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE COURSE; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEINURIA; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; ALDOSTERONE; ALDOSTERONE SYNTHASE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC;

EID: 52649099354     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2008.01005.x     Document Type: Article

References (36)

1. Cooper ME, Johnson CI. Optimizing treatment of hypertension in patients with diabetes. JAMA 2000 283: 3177 9.
2. Scheen AJ. Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system. Drugs 2004 64: 2537 65.
3. Jandeleit-Dahm K, Tikellis C, Reid CM, Johnston CI, Cooper ME. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J. Hypertens. 2005 23: 463 73.
4. Hansson L, Lindholm LH, Niskanen L et al. Effect of angiotensin- converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999 353: 611 16.
5. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high risk patients: The Heart Outcomes Prevention Evaluation study investigators (HOPE). N. Engl. J. Med. 2000 342: 145 53.
6. Dahlof B, Devereux RB, Kjeldsen SE et al. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): A randomized trial against atenolol. Lancet 2002 359: 995 1003.
7. Kjeldsen SE, Julius S, Mancia G et al. VALUE Trial Investigators. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: The VALUE trial. J. Hypertens 2006 24: 1405 12.
8. Mezzano SA, Ruiz-Ortega M, Egido J. Angiotensin II and renal fibrosis. Hypertension 2001 38: 635 8.
9. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CT Jr. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998 31: 451 8.
10. Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J. Clin. Invest. 1996 98: 1063 8.
11. Rocha R, Rudolph AE, Frierdich GE et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am. J. Physiol. Heart Circ. Physiol. 2002 283: H1802 H1810.
12. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT. Aldosterone-induced inflammation in the rat heart: Role of oxidative stress. Am. J. Pathol. 2002 161: 1773 81.
13. Williams JS, Williams GH. 50th anniversary of aldosterone. J. Clin. Endocrinol. Metab. 2003 88: 2364 72.
14. Davies E, Holloway CD, Ingram MC et al. Aldosterone excretion rate and blood pressure in essential hypertension are related to polymorphic differences in the aldosterone synthase gene CYP11B2. Hypertension 1999 33: 703 7.
15. Sookoian S, Gianotti TF, Gonzalez CD, Pirola CJ. Association of the C-344T aldosterone synthase gene variant with essential hypertension: A meta-analysis. J. Hypertens. 2007 25: 5 13.
16. Schjoedt KJ, Lajer M, Anderson S, Tarnow L, Rossing P, Parving HH. Aldosterone synthase (CYP11B2)-344T/C polymorphism and renoprotective response to losartan treatment in diabetic nephropathy. Scand. J. Clin. Lab. Invest. 2006 66: 173 80.
17. Fujisawa G, Okada K, Muto S et al. Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats. Kidney Int. 2004 66: 1493 502.
18. Miric G, Dallemagne C, Endre Z. Reversal of cardiac and renal fibrosis by pirfenidine and spironolactone in streptozotocin-diabetic rats. Br. J. Pharmacol. 2001 133: 687 94.
19. Nitta K, Uchida K, Nihei H. Spironolactone and angiotensin receptor blocker in nondiabetic renal diseases. Am. J. Med. 2004 117: 444 5.
20. Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003 41: 64 8.
21. Jo I, Ahn Y, Lee J, Shin KR, Lee HK, Shin C. Prevalence, awareness, treatment, control and risk factors of hypertension in Korea: The Ansan study. J. Hypertens. 2001 19: 1523 32.
22. Gavin JR, Alberti KG, Davidson MB et al. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003 26 (Suppl 1 S5 S20.
23. Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. Meta-analysis of randomized clinical trials. Diabetes Metab. 2004 30: 487 96.
24. Engeli S. Role of the renin-angiotensin-aldosterone system in the metabolic syndrome. Contrib. Nephrol. 2006 151: 122 34.
25. Jefic D, Mohiuddin N, Alsabbagh R, Fadanelli M, Steigerwalt S. The prevalence of primary aldosteronism in diabetic patients. J. Clin. Hypertens. (Greenwich) 2006 8:253 6.
26. Hollenberg NK, Stevanovic R, Agarwal A et al. Plasma aldosterone concentration in the patient with diabetes mellitus. Kidney Int. 2004 65:1435 9.
27. Umpierrez GE, Temponi D, Cantey P et al. Primary aldosteronism in diabetic subjects with resistant hypertension. Diabetes Care 2007 30:1699 703.
28. Bassett MH, Zhang Y, Clyne C, White PC, Rainey WE. Differential regulation of aldosterone synthase and 11β-hydroxylase transcription by steroidogenic factor-1. J. Mol. Endocrinol. 2002 28:125 35.
29. White PC, Slutsker L. Haplotype analysis of CYP11B2. Endocr. Res. 1995 21:437 42.
30. Iwai N, Kajimoto K, Tomoike H, Takashima N. Polymorphism of CYP11B2 determines salt sensitivity in Japanese. Hypertension 2007 49:825 31.
31. Safar ME, Cattan V, Lacolley P et al. Aldosterone synthase gene polymorphism, stroke volume and age-related changes in aortic pulse wave velocity in subject with hypertension. J. Hypertens. 2005 23:1159 66.
32. Ranade K, Wu KD, Olivier M et al. Genetic variation in aldosterone synthase predicts plasma glucose levels. Proc Natl Acad Sci USA 2001 98:13219 31244.
33. Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms. Diab. Metab 2004 30:498 505.
34. Tikellis C, Wookey PJ, Candido R, Andrikopoulos S, Thomas Mc, Cooper ME. Improved islet morphology after blockade of the renin-angiotensin system in the ZDF rat. Diabetes 2004 53:989 97.
35. Lajer M, Schjoedt KJ, Jacobsen P, Tarnow L, Parving HH. Aldosterone synthase (CYP11B2)-344T/C polymorphism is not associated with the initiation and progression of diabetic nephropathy in Caucasian type 1 diabetic patients. Diabet. Med. 2006 23:675 80.
36. Prasad P, Tiwari AK, Kumar KP et al. Chronic renal insufficiency among Asian Indians with type 2 diabetes: I. Role of RAAS gene polymorphisms. BMC Med. Genet. 2006 7:42 50.